Trp53(−/−) tumours by contrast, had a slower proliferation rate (Supplementary Fig. 2a, Table f) and at 12 weeks displayed immune responses closer to the wt p53 controls (Fig. 4c, d), compared with the isogenic mutant tumours. This evidence concerns the gene TP53 and neoplasm.